Tectonic Therapeutic, Inc.
NASDAQ:TECXBiotechnology
-$0.29 today
- Market cap
- $411.32M
- Beta
- 1.22
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.45
Volume 0.17M
Average 0.20M
TECX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Tectonic Therapeutic, Inc.NASDAQ: TECX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $25.24M (cash outflow) rose 58.7% year over year, behind the +96.5% change in trailing-twelve-month net income. Sequentially, it fell 28.2% from the prior quarter. Over 3 fiscal years it compounded at +1220.8% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$96.5M (+30.1%) for the fiscal year ending Dec 2026, a step up from the +27.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$25.24M-28.2% QoQ
- Last fiscal yearDec 2025
- -$74.15M+27.9% YoY
- LTMMar 2026
- -$115.3M+96.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +58.7% | -29.5% | -88.2 pp |
| 1 year | +27.9% | +30.1% | +2.2 pp |
| 3-year CAGR | +1220.8% | +12.0% | -1208.8 pp |
| 5-year CAGR | +5.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (74.15M) USD
- Year-over-year change
- -27.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (74.15M) | -27.9% |
| FY2024 | 2024-12-31 | (57.98M) | -35.4% |
| FY2023 | 2023-12-31 | (42.82M) | -132973.3% |
| FY2022 | 2022-12-31 | (32.18K) | +99.6% |
| FY2021 | 2021-12-31 | (8.93M) | — |
Net Income vs competitors
How TECX compares with its peers on the latest reported figures
- TECX's LTM Mar 2026 net income of $115.3M is the 3rd largest of the 4 companies compared; the peer median is $222.97M.
- Its year-over-year change of +96.5% is the highest of 4, against a peer median of +22.9%.
- Over three fiscal years its annual growth of +1220.8% compares with a peer median of +30.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $291.03M | +62.6% | +40.1% | — | |
GENBGenerate Biomedicines, Inc. | FY2025 | $222.97M | +22.9% | — | 699.1% |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | $115.3M | +96.5% | +1220.8% | — |
SEPNSepterna, Inc. | LTM Sep 2026 | $59M | +0.3% | +20.9% | 61.3% |
| Peer median (excluding TECX) | $222.97M | +22.9% | +30.5% | 380.2% | |
Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.93M) | (32.18K) | (42.82M) | (57.98M) | (74.15M) |
| Depreciation & Amortization | 364K | 1.01K | 1.48M | 1.65M | 1.38M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 639K | 1.12K | 1.12M | 3.49M | 10.5M |
| Change in Working Capital | 1.92M | (7.4M) | (584K) | (10.28M) | (70K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.45M | (3.1M) | (165K) | (1.42M) | 116K |
| Other Working Capital | 464K | (4.3M) | (419K) | (8.86M) | (186K) |
| Other Non-Cash Items | (6.45M) | (89.78M) | 127K | 4.04M | 2.27M |
| Operating Cash Flow | (12.45M) | (97.21M) | (40.68M) | (59.08M) | (60.08M) |
| Capital Expenditures | (2.12M) | (267K) | (279K) | (156K) | (208K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 70K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (2.12M) | (267K) | (279K) | (156K) | (138K) |
| Debt Repayment | 3.61M | (393K) | (499K) | (475K) | (489K) |
| Common Stock Issued | 2K | 262K | 34.13M | 94.6M | 174.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 393K | 121K | 77.59M | (485K) |
| Financing Cash Flow | 41.42M | 262K | 33.75M | 171.71M | 173.36M |
| Effect of Forex Changes | 0 | 492K | 16K | (8K) | (95K) |
| Net Change in Cash | 26.84M | (96.72M) | (7.2M) | 112.47M | 113.04M |
| Free Cash Flow | (14.58M) | (97.48M) | (40.96M) | (59.24M) | (60.29M) |
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Intrinsic Alpha fair value
Locked
Current Price
$21.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.